Status:
COMPLETED
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Lead Sponsor:
Autotelicbio
Conditions:
Solid Tumor
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and...
Detailed Description
This clinical trial is conducted by dividing into two cohorts according to the dose of the test drug, starting with Cohort 1, and confirming whether DLT occurs until 14 days after the 2nd cycle of the...
Eligibility Criteria
Inclusion
- Adults over 19 years old on the day of consent
- Pathologically confirmed solid cancer
- Patients with advanced or metastatic solid timour failed or tolerable with standard therapy.
- A person who has a tumor lesion that can safely undergo tissue biopsy during administration of the test drug and can provide tissues stored at the clinical trial agency or tissue obtained from a tissue biopsy conducted before the first administration of the test drug
Exclusion
- Those who have been treated with IL-2 or TGF-β inhibitors other than test drugs (e.g., anti-sense oligonucleotide, antibody, TGF-b receptor inhibitor)
- Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment.
- Immunotherapy within 2 weeks prior to first dose of study treatment.
- Major surgery within 4 weeks prior to first dose of study treatment.
Key Trial Info
Start Date :
March 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 21 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04862767
Start Date
March 9 2021
End Date
August 21 2023
Last Update
January 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080